Michaela Bártů

Michaela Bártů

Auto-generated profile, based on publicly available information

Michaela Bártů

Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ITIvana Ticha
Ivana Ticha
JHJan Hojny
Jan Hojny
RMRomana Michalkova
Romana Michalkova
OKOndrej Kodet
Ondrej Kodet
EKEva Krkavcova
Eva Krkavcova
PDPavel Dundr
Pavel Dundr
The most common histological subtypes of cutaneous melanoma include superficial spreading and nodular melanoma. However, the spectrum of somatic mutations developed in those lesions and all potential druggable targets have not yet been fully elucidated. We present the results of a sequence capture NGS analysis of 114 primary nodular and superficial spreading melanomas identifying driver mutations using biostatistical, immunohistochemical and/or functional approach. The spectrum and frequency of pathogenic or likely pathogenic variants were identified across 54 evaluated genes, including 59 novel mutations, and the newly identified TP53 loss-of-function mutations p.(L194P) and p.(R280K). Frequently mutated genes most commonly affected the MAPK pathway, followed by chromatin remodeling, and cell cycle regulation. Frequent aberrations were also detected in the genes coding for proteins involved in DNA repair and the regulation and modification of cellular tight junctions. Furthermore, relatively frequent mutations were described in KDR and MET, which represent potential clinically important targets. Those results suggest that with the development of new therapeutic possibilities, not only BRAF testing, but complex molecular testing of cutaneous melanoma may become an integral part of the decision process concerning the treatment of patients with melanoma.

31 August 2019 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
MGMária Gregová
Mária Gregová
JHJan Hojný
Jan Hojný
KNKristýna Němejcová
Kristýna Němejcová
MBMichaela Bártů
Michaela Bártů
MMMichal Mára
Michal Mára
PDPavel Dundr
Pavel Dundr

11 November 2017 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
MDMiroslav Důra
Miroslav Důra
KNKristyna Nemejcova
Kristyna Nemejcova
RJRadek Jakša
Radek Jakša
MBMichaela Bártů
Michaela Bártů
OKOndrej Kodet
Ondrej Kodet
PDPavel Dundr
Pavel Dundr

19 December 2015 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
KNKristyna Nemejcova
Kristyna Nemejcova
ITIvana Tichá
Ivana Tichá
PKPetra Kleiblová
Petra Kleiblová
MBMichaela Bártů
Michaela Bártů
DCDavid Cibula
David Cibula
PDPavel Dundr
Pavel Dundr

1 January 2018 in Folia Biologica
Verified
Journal Article
Open access
PDF file
MBMichaela Bártů
Michaela Bártů
PDP. Dundr
P. Dundr
KNK. Němejcová
K. Němejcová
ITI. Tichá
I. Tichá
HHH. Hojný
H. Hojný
NHN. Hájková
N. Hájková
Hepatocyte nuclear factor 1-β is a transcription factor which plays a crucial role during ontogenesis in the differentiation of visceral endoderm from primitive endoderm, and is especially important for the normal development of the kidney, urogenital tract, gastrointestinal tract, liver, and pancreas. Despite the growing knowledge about the potential involvement of hepatocyte nuclear factor 1-β in the process of carcinogenesis, the exact underlying mechanism that would explain its rather varied effects in different tumours has not been sufficiently investigated. Most of the data regarding the significance of hepatocyte nuclear factor 1-β arise from genome- wide association studies and is concerned with the influence of single-nucleotide polymorphisms of hepatocyte nuclear factor 1-β on either the increased or decreased susceptibility to certain types of cancer. However, the influence of both the germinal and somatic mutations of this gene on the process of carcinogenesis is still poorly understood. According to current data, in some tumours hepatocyte nuclear factor 1-β acts as a protooncogene, while in others as a tumour suppressor gene, although the reasons for this are not clear. The exact incidence of hepatocyte nuclear factor 1-β mutations and the spectrum of tumours in which they may play a role in the process of carcinogenesis remain unknown. From the practical point of view, immunohistochemical expression of hepatocyte nuclear factor 1-β can be used in differential diagnostics of certain tumours, especially clear cell carcinoma. In our article we review the current knowledge regarding the significance of hepatocyte nuclear factor 1-β in carcinogenesis.

7 September 2023 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
MBMichaela Kendall Bártů
Michaela Kendall Bártů
KNKristýna Němejcová
Kristýna Němejcová
RMRomana Michálková
Romana Michálková
ISIvana Stružinská
Ivana Stružinská
NHNikola Hájková
Nikola Hájková
PDPavel Dundr
Pavel Dundr